IGSC 20%

BIOLOGICAL3 trials

Sponsors

Grifols Therapeutics LLC

Conditions

Primary Immunodeficiency

Phase 3

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

CompletedNCT02604810

Grifols Therapeutics LLCPrimary Immunodeficiency

Start: 2016-01-31End: 2017-12-31Updated: 2019-10-04

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

CompletedNCT02806986

Grifols Therapeutics LLCPrimary Immunodeficiency

Start: 2016-06-30End: 2019-05-15Updated: 2020-06-16

Phase 4

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

CompletedNCT04566692

Grifols Therapeutics LLCPrimary Immunodeficiency

Start: 2020-11-24End: 2022-07-25Updated: 2023-09-29

Related Papers

Immune Globulin Subcutaneous, Human – Klhw 20% for Primary Humoral Immunodeficiency: An Open-Label, Phase III Study

Immunotherapy2019-10-176 citations